• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Despite clinical and scientific advancements, heart failure is the major cause of morbidity
and mortality worldwide. Both mitochondrial dysfunction and inflammation contribute to the …

Sarcoidosis is a systemic granulomatous disease of unknown cause. Sarcoidosis involving
the heart, ie, cardiac sarcoidosis, affects the prognosis of patients significantly as it may lead …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Heart failure (HF) has been singled out as an epidemic and is a staggering clinical and
public health problem, associated with significant mortality, morbidity, and healthcare …

ESC Guidelines 2389 disclosure forms are kept on file at the European Heart House,
headquarters of the ESC. Any changes in conflict of interest that arise during the writing …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Despite an increase in manuscripts describing epidemiological aspects of heart failure since
the 1990s, 1 additional information is still needed, as indicated by various editorials. w2 w3 …

Heart failure (HF) is a major and growing public health problem in the United States.
Approximately 5 million patients in this country have HF, and over 550 000 patients are …

Late-breaking clinical trials presented at the 2005, 2006, and 2007 annual scientific
meetings of the ACCF, AHA, and European Society of Cardiology, as well as selected other …